Literature DB >> 7513781

Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy.

J O Jørgensen1, N Møller, J Møller, J Weeke, W F Blum.   

Abstract

The interrelationship between insulin-like growth factors (IGFs) and their major binding proteins (IGFBPs) as a function of disease activity in acromegaly has not previously been prospectively evaluated. We studied basal and insulin-stimulated serum levels of IGF-I and -II and IGFBP-1, -2, and -3 in six acromegalic patients before and 2 months after successful adenomectomy compared with a group of sex- and age-matched healthy, untreated subjects. All were studied postabsorptively (11 AM) and at the end of a 2-hour euglycemic glucose clamp (0.4 mU insulin/kg x min). Serum IGF-I levels (mean +/- SE) were elevated in acromegaly but were normalized following therapy (basal state IGF-I [micrograms/L], 857 +/- 119 [active] v 255 +/- 65 [postoperative] v 190 +/- 20 [control]). Serum IGF-II levels did not change following therapy and were similar to those of the control group. IGF levels did not change during the clamp. Serum IGFBP-3 levels were elevated in active acromegaly, but were normalized after therapy (basal state IGFBP-3 [micrograms/L] 6,983 +/- 612 [active] v 3,939 +/- 504 [postop] v 3,358 +/- 125 [control]). The molar ratio of (IGF-I+IGF-II): IGFBP-3 was similar in all studies. Serum IGFBP-1 interacted significantly with time in all studies, exhibiting a gradual decrease in the basal state and ensued by further suppression during the clamp. Insulin and IGFBP-1 correlated inversely in the pooled data and in the acromegalic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513781     DOI: 10.1016/0026-0495(94)90199-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.

Authors:  H Yu; J Mistry; M J Nicar; M J Khosravi; A Diamandis; J van Doorn; A Juul
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 2.  Somatostatin analogue treatment of neuroendocrine tumours.

Authors:  W W de Herder; A J van der Lely; S W Lamberts
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

3.  Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.

Authors:  C Invitti; L Fatti; M G Camboni; L Porcu; L Danesi; G Delitala; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

4.  Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly.

Authors:  H S Chen; H D Lin
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

Review 5.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.